Through partnerships with Bicycle and Metagenomi, Ionis is working on new chemistries and novel medicines. It is also expanding manufacturing capacity to enable its scientific growth.

Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.

Astute students of leadership can glean something from every approach. In Vivo asked five Danish biopharma executives to reflect on what characterizes Danish leadership. They shared insights on the defining features of a Danish approach, its pros and cons, and what lessons they can offer leaders from other countries.

COVID-19 has highlighted the need for potent, safe and effective antiviral therapies for infectious diseases and now one well-known Chinese researcher is tackling hepatitis B and D though a homegrown drug discovery approach. He talks to Scrip in this wide-ranging audio interview.